Back to today’s briefing

Story perspectives

Xanamem: Promising Alzheimer's Treatment Set for 2027 Launch

1/6/2025

33 2

Summary

Story summary

Actinogen's groundbreaking drug, Xanamem, targets Alzheimer's by inhibiting cortisol production in the brain. With trials underway in the U.S. and Australia, early results are encouraging, hinting at a future where Alzheimer's treatment could be revolutionized. If all goes well, Xanamem may be available by 2027, offering hope for early intervention in at-risk patients.

1 of 1

Story summary

Actinogen's groundbreaking drug, Xanamem, targets Alzheimer's by inhibiting cortisol production in the brain. With trials underway in the U.S. and Australia, early results are encouraging, hinting at a future where Alzheimer's treatment could be revolutionized. If all goes well, Xanamem may be available by 2027, offering hope for early intervention in at-risk patients.